Corrigendum to “Hyperphenylalaninemia in the Czech Republic: genotype–phenotype correlations and in silico analysis of novel missense mutations” [Clin Chim Acta 419C: (2013) 1–10] (Clinica Chimica Acta (2013) 419 (1–10), (S0009898113000211), (10.1016/j.cca.2013.01.006));Hyperphenylalaninemia in the Czech Republic: Genotype-phenotype correlations and in silico analysis of novel missense mutations

Clinica Chimica Acta

Volumn 419, Issue , 2013, Pages 1-10

  Réblová, Kamila ^a   Hrubá, Zuzana ^b   Procházková, Dagmar ^a   Pazdírková, Renata ^c   Pouchlá, Slávka ^b   Fajkusová, Lenka ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Genotype phenotype relationship; Hyperphenylalaninemia; Molecular modelling; Phenylalanine hydroxylase

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; CYSTEINE; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; PHENYLALANINE; PROLINE; SERINE; THREONINE; TRYPTOPHAN; TYROSINE; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BIOINFORMATICS; COMPUTER MODEL; CONTROLLED STUDY; CZECH REPUBLIC; DNA DETERMINATION; ENZYME ACTIVE SITE; GENE DELETION; GENE DUPLICATION; GENE REARRANGEMENT; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERPHENYLALANINEMIA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAH GENE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

EID: 84874348803     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.10.010     Document Type: Erratum

References (66)

1. Trefz F.K., Scheible D., Frauendienst-Egger G., Korall H., Blau N. Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Mol Genet Metab 2005, 86(Suppl. 1):S75-S80.
2. Kure S., Hou D.C., Ohura T., et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999, 135:375-378.
3. Blau N., Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 2004, 82:101-111.
4. Levy H.L., Milanowski A., Chakrapani A., et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
5. Muntau A.C., Roschinger W., Habich M., et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 2002, 347:2122-2132.
6. Bernegger C., Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol Genet Metab 2002, 77:304-313.
7. Fiege B., Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr 2007, 150:627-630.
8. Burton B.K., Grange D.K., Milanowski A., et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007, 30:700-707.
9. Pey A.L., Martinez A. The activity of wild-type and mutant phenylalanine hydroxylase and its regulation by phenylalanine and tetrahydrobiopterin at physiological and pathological concentrations: an isothermal titration calorimetry study. Mol Genet Metab 2005, 86(Suppl. 1):S43-S53.
10. Gersting S.W., Kemter K.F., Staudigl M., et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet 2008, 83:5-17.
11. Muntau A.C., Gersting S.W. Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism. J Inherit Metab Dis 2010, 33:649-658.
12. Aguado C., Perez B., Ugarte M., Desviat L.R. Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells. FEBS Lett 2006, 580:1697-1701.
13. Staudigl M., Gersting S.W., Danecka M.K., et al. The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Hum Mol Genet 2011, 20:2628-2641.
14. Erlandsen H., Pey A.L., Gamez A., et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 2004, 101:16903-16908.
15. Giovannini M., Verduci E., Salvatici E., Fiori L., Riva E. Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 2007, 30:145-152.
16. Trefz F.K., Scheible D., Gotz H., Frauendienst-Egger G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J Inherit Metab Dis 2009, 32:22-26.
17. Zurfluh M.R., Zschocke J., Lindner M., et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 2008, 29:167-175.
18. Fusetti F., Erlandsen H., Flatmark T., Stevens R.C. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J Biol Chem 1998, 273:16962-16967.
19. Knappskog P.M., Flatmark T., Aarden J.M., Haavik J., Martinez A. Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. Eur J Biochem 1996, 242:813-821.
20. Waters P.J., Parniak M.A., Akerman B.R., Scriver C.R. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. Mol Genet Metab 2000, 69:101-110.
21. Pey A.L., Stricher F., Serrano L., Martinez A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet 2007, 81:1006-1024.
22. Gjetting T., Petersen M., Guldberg P., Guttler F. In vitro expression of 34 naturally occurring mutant variants of phenylalanine hydroxylase: correlation with metabolic phenotypes and susceptibility toward protein aggregation. Mol Genet Metab 2001, 72:132-143.
23. Kobe B., Jennings I.G., House C.M., et al. Structural basis of autoregulation of phenylalanine hydroxylase. Nat Struct Biol 1999, 6:442-448.
24. Erlandsen H., Stevens R.C. The structural basis of phenylketonuria. Mol Genet Metab 1999, 68:103-125.
25. Adzhubei I.A., Schmidt S., Peshkin L., et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
26. Ng P.C., Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001, 11:863-874.
27. Yue P., Melamud E., Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006, 7:166.
28. Guerois R., Nielsen J.E., Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 2002, 320:369-387.
29. Kozak L., Hrabincova E., Kintr J., et al. Identification and characterization of large deletions in the phenylalanine hydroxylase (PAH) gene by MLPA: evidence for both homologous and non-homologous mechanisms of rearrangement. Mol Genet Metab 2006, 89:300-309.
30. Erlandsen H., Stevens R.C. A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. J Inherit Metab Dis 2001, 24:213-230.
31. Humphrey W., Dalke A., Schulten K. VMD-visual molecular dynamics. J Mol Graph Model 1996, 14:33-38.
32. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993, 234:779-815.
33. Gresh N., Sponer J.E., Spackova N., Leszczynski J., Sponer J. Theoretical study of binding of hydrated Zn(II) and Mg(II) cations to 5D́-guanosine monophosphate. Toward polarizable molecular mechanics for DNA and RNA. J Phys Chem B 2003, 107:8669-8681.
34. Case D.A. AMBER 10 2008, University of California, San Francisco.
35. Mirkovic N., Marti-Renom M.A., Weber B.L., Sali A., Monteiro A.N. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 2004, 64:3790-3797.
36. Wang Z., Moult J. SNPs, protein structure, and disease. Hum Mutat 2001, 17:263-270.
37. Chothia C. The nature of the accessible and buried surfaces in proteins. J Mol Biol 1976, 105:1-12.
38. Zamyatin A.A. Protein volume in solution. Prog Biophys Mol Biol 1972, 24:107-123.
39. Bordo D., Argos P. Suggestions for "safe" residue substitutions in site-directed mutagenesis. J Mol Biol 1991, 217:721-729.
40. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974, 185:862-864.
41. Luu T.D., Rusu A.M., Walter V., et al. MSV3d: database of human MisSense variants mapped to 3D protein structure. Database (Oxford) 2012, 10.1093/database/bas1018.
42. Henikoff S., Henikoff J.G. Amino acid substitution matrices from protein blocks. PNAS 1992, 89:10915-10919.
43. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 2006, 65:712-725.
44. Dang L.X., Kollman P.A. Free energy of association of the K+: 18-crown-6 complex in water: a new molecular dynamics study. J Phys Chem 1995, 99:55-58.
45. Smith D.E., Dang L.X. Computer simulations of NaCl association in polarizable water. J Chem Phys 1994, 100:3757-3766.
46. Spackova N., Reblova K., Sponer J. Structural dynamics of the Box C/D RNA kink-turn and its complex with proteins: the role of the A-minor 0 interaction, long-residency water bridges, and structural ion-binding sites revealed by molecular simulations. J Phys Chem B 2010, 114:10581-10593.
47. Kozak L., Kuhrova V., Blazkova M., et al. Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. Hum Genet 1995, 96:472-476.
48. Kozak L., Blazkova M., Kuhrova V., Pijackova A., Ruzickova S., St'astna S. Mutation and haplotype analysis of phenylalanine hydroxylase alleles in classical PKU patients from the Czech Republic: identification of four novel mutations. J Med Genet 1997, 34:893-898.
49. Guldberg P., Henriksen F.F., Thony B., Blau N., Güttlet F. Molecular heterogeneity of nonphenylketonuria hyperphenylalaninemia in 25 Danish patients. Genomics 1994, 21:453-455.
50. Takarada Y., Kalanin J., Yamashita K., Ohtsuka N., Kagawa S., Matsuoka A. Phenylketonuria mutant alleles in different populations: missense mutation in exon 7 of phenylalanine hydroxylase gene. Clin Chem 1993, 39:2354-2355.
51. Dobrowolski S.F., Borski K., Ellingson C.C., Koch R., Levy H.L., Naylor E.W. A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin. J Hum Genet 2009, 54:335-339.
52. Sterl E., Paul K., Paschke E., et al. Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients. J Inherit Metab Dis 2013, 36:7-13.
53. Aulehla-Scholz C., Heilbronner H. Mutational spectrum in German patients with phenylalanine hydroxylase deficiency. Hum Mutat 2003, 21:399-400.
54. Daniele A., Scala I., Cardillo G., et al. Functional and structural characterization of novel mutations and genotype-phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy. FEBS J 2009, 276:2048-2059.
55. Pey A.L., Desviat L.R., Gamez A., Ugarte M., Perez B. Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum Mutat 2003, 21:370-378.
56. Yue P., Li Z., Moult J. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 2005, 353:459-473.
57. Cheatham T.E. Simulation and modeling of nucleic acid structure, dynamics and interactions. Curr Opin Struct Biol 2004, 14:360-367.
58. Ditzler M.A., Otyepka M., Sponer J., Walter N.G. Molecular dynamics and quantum mechanics of RNA: conformational and chemical change we can believe in. Acc Chem Res 2010, 43:40-47.
59. Klepeis J.L., Lindorff-Larsen K., Dror R.O., Shaw D.E. Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struct Biol 2009, 19:120-127.
60. Shaw D.E., Maragakis P., Lindorff-Larsen K., et al. Atomic-level characterization of the structural dynamics of proteins. Science 2010, 330:341-346.
61. Cozzi R., Nuccitelli A., D'Onofrio M., et al. New insights into the role of the glutamic acid of the E-box motif in group B Streptococcus pilus 2a assembly. FASEB J 2012, 26:2008-2018.
62. Guo J., Ning L., Ren H., Liu H., Yao X. Influence of the pathogenic mutations T188K/R/A on the structural stability and misfolding of human prion protein: insight from molecular dynamics simulations. Biochim Biophys Acta 2012, 1820:116-123.
63. McDonald J.D., Charlton C.K. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997, 39:402-405.
64. Sarkissian C.N., Boulais D.M., McDonald J.D., Scriver C.R. A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia. Mol Genet Metab 2000, 69:188-194.
65. Shedlovsky A., McDonald J.D., Symula D., Dove W.F. Mouse models of human phenylketonuria. Genetics 1993, 134:1205-1210.
66. Gersting S.W., Lagler F.B., Eichinger A., et al. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet 2010, 19:2039-2049.